ANVS - Annovis Bio Inc
2.5
-0.080 -3.200%
Share volume: 435,024
Last Updated: 03-11-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.16%
PREVIOUS CLOSE
CHG
CHG%
$2.58
-0.08
-0.03%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
| Report Date | 05-10-2024 | 08-14-2024 | 11-08-2024 | 03-21-2025 | 05-13-2025 | 08-12-2025 | 11-12-2025 | |
| Assets | ||||||||
| Total Assets | 7.813 M | 5.046 M | 14.362 M | 13.926 M | 26.737 M | 21.455 M | 17.189 M | |
| Current Assets | 7.813 M | 5.046 M | 14.362 M | 13.926 M | 26.737 M | 21.455 M | 17.189 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 3.137 M | 3.998 M | 12.637 M | 10.552 M | 22.236 M | 17.130 M | 15.286 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 7.813 M | 5.046 M | 14.362 M | 13.926 M | 26.737 M | 21.455 M | 17.189 M | |
| Total liabilities | 11.167 M | 6.797 M | 7.298 M | 4.618 M | 2.683 M | 3.124 M | 4.033 M | |
| Total current liabilities | 4.870 M | 4.057 M | 5.391 M | 3.881 M | 2.504 M | 2.805 M | 3.734 M | |
| Accounts Payable | 4.107 M | 3.395 M | 4.099 M | 2.306 M | 1.370 M | 974.311 K | 2.112 M | |
| Other liabilities | 6.297 M | 2.740 M | 1.907 M | 737.000 K | 179.000 K | 319.000 K | 299.000 K | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 6.297 M | 2.740 M | 1.907 M | 737.000 K | 179.000 K | 319.000 K | 299.000 K | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | -3.354 M | -1.751 M | 7.064 M | 9.308 M | 24.054 M | 18.330 M | 13.156 M | |
| Common stock | 107.972 M | 114.596 M | 136.049 M | 144.157 M | 164.440 M | 164.937 M | 167.025 M | |
| Retained earnings | -111.326 M | -116.346 M | -128.985 M | -134.849 M | -140.387 M | -146.607 M | -153.869 M |